LICENSE AGREEMENT by and among HUTCHMED LIMITED (和记黄埔医药（上海）有限公司) and TAKEDA PHARMACEUTICALS INTERNATIONAL AG and HUTCHMED (CHINA) LIMITED (和黄医药（中国）有限公司) January 23, 2023License Agreement • February 28th, 2023 • HUTCHMED (China) LTD • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (the “Agreement”) is entered into on this 23rd day of January, 2023 (the “Execution Date”), by and among HUTCHMED Limited (和记黄埔医药（上海）有限公司), a company organized under the laws of the People’s Republic of China, having its registered office at Building 4, 720 Cailun Road, China (Shanghai) Pilot Free Trade Zone, Shanghai 201203, P. R. China (“HUTCHMED”), and Takeda Pharmaceuticals International AG, a company organized under the laws of Switzerland, having its principal place of business located at Thurgauerstrasse 130, 8152 Glattpark (Opfikon), Switzerland (“Company”) and, solely for the purposes of Section 11.18 (Guarantees), HUTCHMED (China) Limited (和黄医药（中国）有限公司), a company organized and existing under the laws of the Cayman Islands with its principal offices at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (“HUTCHMED GUARANTOR”). HUTCHMED and Company may each be referred to herein individually as a “Party” and collectively as the “Parties.”
